Martin Herman, MD
Neurology · Edison, NJNPI 1902862345
Payments from drug & device makers
Across 32 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$200
- Stryker$142
- Bristol Myers Squibb$81
- Lilly USA, LLC$68
- UCB, Inc.$44
- AbbVie$42
- plus $231 from 10 others
What the payments were for
- Food & beverage$808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 2 | $200 |
| Stryker | 2 | $142 |
| Bristol Myers Squibb | 5 | $81 |
| Lilly USA, LLC | 4 | $68 |
| UCB, Inc. | 3 | $44 |
| AbbVie | 3 | $42 |
| SK Life Science, Inc. | 2 | $34 |
| Merz Pharmaceuticals, LLC | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Exact Sciences | 1 | $24 |
| Biogen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$808 in reported general payments places this provider in the 35th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 11 | $83,352 |
| LamictalLamotrigine | 23 | $24,286 |
| Nurtec OdtRimegepant Sulfate | 11 | $11,461 |
| Memantine Hcl | 148 | $4,995 |
| Levetiracetam | 86 | $4,133 |
| Carbamazepine ErCarbamazepine | 12 | $3,101 |
| Donepezil Hcl | 249 | $2,303 |
| Oxcarbazepine | 28 | $2,299 |
| Rivastigmine | 12 | $2,134 |
| Lamotrigine ErLamotrigine | 13 | $1,408 |
| Levetiracetam ErLevetiracetam | 20 | $1,359 |
| Lacosamide | 20 | $1,301 |
| Topiramate | 43 | $928 |
| Lamotrigine | 29 | $913 |
| Divalproex Sodium | 42 | $906 |
Paid to pharmacies, not to this prescriber.
Other neurology in Edison
- Sue MingEdison$247K
- Jawad KirmaniEdison$130K
- Diosely SilveiraEdison$113K
- Igor SobolEdison$103K
- Siddharth KapoorEdison$87K
- Wei Wei MaEdison$85K
- Joseph LandolfiEdison$82K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.